Symptom Response in NSCLC Patients Treated with Erlotinib: QOL Analysis of the NCIC CTG BR.21 Trial

Reviewer: S. Jack Wei, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 17 de mayo del 2005

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015